- Home
- NUKK vs ACHV Comparison
NUKK vs ACHV Comparison
Compare NUKK & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- ACHV
- Stock Information
- Founded
- NUKK 2013
- ACHV N/A
- Country
- NUKK United States
- ACHV Canada
- Employees
- NUKK N/A
- ACHV N/A
- Industry
- NUKK Blank Checks
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NUKK Finance
- ACHV Health Care
- Exchange
- NUKK Nasdaq
- ACHV Nasdaq
- Market Cap
- NUKK 117.3M
- ACHV 126.9M
- IPO Year
- NUKK N/A
- ACHV N/A
- Fundamental
- Price
- NUKK $16.90
- ACHV $3.09
- Analyst Decision
- NUKK
- ACHV Strong Buy
- Analyst Count
- NUKK 0
- ACHV 5
- Target Price
- NUKK N/A
- ACHV $14.80
- AVG Volume (30 Days)
- NUKK 5.4M
- ACHV 277.4K
- Earning Date
- NUKK 02-24-2025
- ACHV 11-07-2024
- Dividend Yield
- NUKK N/A
- ACHV N/A
- EPS Growth
- NUKK N/A
- ACHV N/A
- EPS
- NUKK N/A
- ACHV N/A
- Revenue
- NUKK $10,752,616.00
- ACHV N/A
- Revenue This Year
- NUKK N/A
- ACHV N/A
- Revenue Next Year
- NUKK N/A
- ACHV N/A
- P/E Ratio
- NUKK N/A
- ACHV N/A
- Revenue Growth
- NUKK N/A
- ACHV N/A
- 52 Week Low
- NUKK $1.30
- ACHV $3.04
- 52 Week High
- NUKK $78.32
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- NUKK 45.72
- ACHV 29.72
- Support Level
- NUKK $22.30
- ACHV $3.12
- Resistance Level
- NUKK $32.90
- ACHV $3.86
- Average True Range (ATR)
- NUKK 7.19
- ACHV 0.21
- MACD
- NUKK -2.89
- ACHV -0.03
- Stochastic Oscillator
- NUKK 1.45
- ACHV 8.33
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically, the majority of its revenue is generated from the United Kingdom and the rest from the United States and Malta.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.